NCT06390501Completed
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This study will test the effects of weekly injections of the glucagon like peptide-1 (GLP-1) agonist semaglutide on energy expenditure and metabolic parameters in a 24 week double-blind, placebo-controlled dose escalation randomized trial. After baseline testing, 52 patients will be randomly assigned to the semaglutide or matching placebo injection group. In addition to taking medication or placebo, all participants will a calorie restricted diet provided by the researchers, providing 600 kcals per day below their estimated baseline requirements. Before and at the end of treatment, weight status, body composition, basal metabolic rate (BEE), 24h energy expenditure, daily total energy expenditure (TEE) for free living, physical activity, energy intake (questionnaire and food table), and hormone parameters for energy homeostasis will be evaluated.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 11 Apr 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 15 Aug 2025
- Lead sponsor
- Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
- Diseases
- Obesity
- NCT number
- NCT06390501
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Apr 2024 to the primary completion date, 15 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgical treatment for past obesity, dieting, or undergoing weight loss treatment
- Irregular diet and lifestyle, unhealthy habits such as smoking, alcohol, and drugs
Other illness
- Patients with metabolic diseases, basic diseases or infectious diseases
- Patients with a personal or family history of medullary thyroid carcinoma (MTC), or patients with rare type 2 multiple endocrine tumor syndrome (MEN 2)
Other
- Weight change exceeding 5 kilograms (11 pounds) in the past 90 days
- Current use of any other GLP1 receptor agonist
- Pregnancy, lactation or expectation to conceive during study period (8) Subject with contraindication to neuroimaging by MRI (9) People with fear of blood and pathologically low blood pressure (10) Use of antibiotics and probiotics within 8 weeks
- 11\) Subject unlikely to adhere to study procedures in opinion of investigator
Who the study is looking for
- Age 18-60 years at time of enrollment
- BMI ≥ 25 kg/m²
Age in the registry: 18 years to 60 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Institute of Advanced Technology Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.